Grifols (NASDAQ:GRFS) Stock Rating Upgraded by Berenberg Bank

Berenberg Bank upgraded shares of Grifols (NASDAQ:GRFS - Free Report) to a strong-buy rating in a report published on Tuesday morning, Zacks.com reports.

Grifols Stock Down 0.9 %

Shares of GRFS traded down $0.08 during mid-day trading on Tuesday, hitting $8.69. 1,370,280 shares of the company traded hands, compared to its average volume of 1,921,992. Grifols has a 1-year low of $5.30 and a 1-year high of $12.15. The company has a quick ratio of 0.80, a current ratio of 1.68 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $5.97 billion, a PE ratio of 8.60 and a beta of 0.50. The business has a 50 day moving average of $8.82 and a 200 day moving average of $7.77.

Grifols (NASDAQ:GRFS - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion for the quarter. Equities research analysts anticipate that Grifols will post 0.79 EPS for the current year.

Hedge Funds Weigh In On Grifols

Several hedge funds have recently modified their holdings of the stock. Brandes Investment Partners LP increased its holdings in Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company's stock worth $117,242,000 after buying an additional 1,481,924 shares during the period. Armistice Capital LLC increased its holdings in Grifols by 18.7% in the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company's stock worth $49,759,000 after buying an additional 1,244,000 shares during the period. Capital World Investors increased its holdings in Grifols by 4.9% in the 1st quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company's stock worth $138,605,000 after buying an additional 961,700 shares during the period. Highland Peak Capital LLC acquired a new position in Grifols in the 2nd quarter worth approximately $5,991,000. Finally, Black Creek Investment Management Inc. grew its stake in shares of Grifols by 7.7% during the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company's stock worth $77,799,000 after purchasing an additional 881,155 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.